Free Trial

Lixte Biotechnology (LIXT) Competitors

Lixte Biotechnology logo
$4.50 +0.14 (+3.21%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$4.50 0.00 (0.00%)
As of 10/17/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LIXT vs. LITS, ENTX, IMUX, ASRT, IZTC, VXRT, UNCY, COEP, CRVO, and XBIT

Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Lite Strategy (LITS), Entera Bio (ENTX), Immunic (IMUX), Assertio (ASRT), Invizyne Technologies (IZTC), Vaxart (VXRT), Unicycive Therapeutics (UNCY), Coeptis Therapeutics (COEP), CervoMed (CRVO), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

Lixte Biotechnology vs. Its Competitors

Lixte Biotechnology (NASDAQ:LIXT) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 14.8% of Lixte Biotechnology shares are held by company insiders. Comparatively, 3.1% of Lite Strategy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Lite Strategy had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Lixte Biotechnology. Lite Strategy's average media sentiment score of 0.78 beat Lixte Biotechnology's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lixte Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lite Strategy
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lixte Biotechnology has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Lite Strategy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Lixte Biotechnology has higher earnings, but lower revenue than Lite Strategy. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/A-$3.59M-$1.29-3.49
Lite Strategy$65.30M1.03-$15.94M-$4.75-0.40

Lixte Biotechnology's return on equity of 0.00% beat Lite Strategy's return on equity.

Company Net Margins Return on Equity Return on Assets
Lixte BiotechnologyN/A N/A -222.90%
Lite Strategy N/A -69.70%-60.80%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Lite Strategy beats Lixte Biotechnology on 6 of the 11 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIXT vs. The Competition

MetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.53M$3.45B$6.15B$10.57B
Dividend YieldN/A2.27%5.72%4.81%
P/E Ratio-3.498.2864.3622.95
Price / SalesN/A485.62610.57131.84
Price / CashN/A46.9237.1060.81
Price / Book-3.7810.4112.236.52
Net Income-$3.59M-$52.77M$3.33B$276.93M
7 Day Performance-5.66%2.31%1.17%1.93%
1 Month Performance-16.97%11.13%6.14%2.19%
1 Year Performance138.11%11.12%59.98%34.99%

Lixte Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIXT
Lixte Biotechnology
0.153 of 5 stars
$4.50
+3.2%
N/A+136.8%$20.53MN/A-3.494News Coverage
Gap Down
LITS
Lite Strategy
N/A$2.48
-4.6%
N/AN/A$88.41M$65.30M-0.52100News Coverage
Gap Down
ENTX
Entera Bio
2.1675 of 5 stars
$1.90
+3.0%
$10.00
+427.7%
+28.4%$86.53M$166K-7.2920News Coverage
IMUX
Immunic
2.5273 of 5 stars
$0.87
-7.0%
$9.50
+987.0%
-49.7%$86.12MN/A-0.9370News Coverage
Analyst Upgrade
ASRT
Assertio
2.8548 of 5 stars
$0.88
-1.4%
$2.38
+169.3%
-31.0%$84.88M$117.10M-1.9620Positive News
IZTC
Invizyne Technologies
N/A$13.30
-0.1%
N/AN/A$83.15MN/A0.0029Gap Up
VXRT
Vaxart
1.9136 of 5 stars
$0.36
-0.6%
$2.00
+460.2%
-55.5%$81.73M$47.40M-1.32120
UNCY
Unicycive Therapeutics
3.0952 of 5 stars
$4.59
-0.3%
$57.00
+1,143.2%
+3.5%$80.95M$680K-1.119
COEP
Coeptis Therapeutics
0.6976 of 5 stars
$16.75
-5.3%
N/A+286.4%$80.74MN/A-2.892Short Interest ↑
CRVO
CervoMed
3.326 of 5 stars
$8.68
+0.7%
$19.29
+122.2%
-49.6%$80.34M$9.74M-3.334Analyst Forecast
XBIT
XBiotech
1.8517 of 5 stars
$2.64
-0.9%
N/A-67.0%$80.34MN/A-2.86100Short Interest ↓

Related Companies and Tools


This page (NASDAQ:LIXT) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners